Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vav proteins are key regulators of card9 signaling for innate antifungal immunity

  • Roth, Susanne
  • Bergmann, Hanna
  • Jaeger, Martin
  • Yeroslaviz, Assa
  • Neumann, Konstantin
  • Koenig, Paul-Albert
  • Prazeres da Costa, Clarissa
  • Vanes, Lesley
  • Kumar, Vinod
  • Johnson, Melissa
  • Menacho-Márquez, Mauricio
  • Habermann, Bianca
  • Tybulewicz, Victor L.
  • Netea, Mihai
  • Bustelo, Xosé R.
  • Ruland, Jürgen
Fungal infections are major causes of morbidity and mortality, especially in immunocompromised individuals. The innate immune system senses fungal pathogens through Syk-coupled C-type lectin receptors (CLRs), which signal through the conserved immune adaptor Card9. Although Card9 is essential for antifungal defense, the mechanisms that couple CLR-proximal events to Card9 control are not well defined. Here, we identify Vav proteins as key activators of the Card9 pathway. Vav1, Vav2, and Vav3 cooperate downstream of Dectin-1, Dectin-2, and Mincle to engage Card9 for NF-κB control and proinflammatory gene transcription. Although Vav family members show functional redundancy, Vav1/2/3 mice phenocopy Card9 animals with extreme susceptibility to fungi. In this context, Vav3 is the single most important Vav in mice, and a polymorphism in human VAV3 is associated with susceptibility to candidemia in patients. Our results reveal a molecular mechanism for CLR-mediated Card9 regulation that controls innate immunity to fungal infections., This work was supported by research grants from the Helmholtz Alliance Preclinical Comprehensive Cancer Center, the DFG (SFB 1054 and RU 695/6-1), and an ERC Advanced Grant (FP7, grant agreement 322865) (to J.R.). The work of X.R.B. has been supported by grants from the Spanish Ministry of Economy and Competitiveness (RD12/0036/0002 and SAF2015-64556-R), Worldwide Cancer Research (14-1248), and the Ramón Areces Foundation. M.G.N. was supported by an ERC Consolidator Grant (310372). V.L.T. was supported by the Francis Crick Institute which receives its core funding from the MRC (FC001194), Cancer Research UK (FC001194) and the Wellcome Trust (FC001194)., Peer Reviewed